DAXOR CORPORATION ANNOUNCES NOVEL FLUORESCENT TRACER AND PHASE-TWO US AIR FORCE CONTRACT AWARD OF $750,000 FOR POINT-OF-CARE OPTICAL BLOOD VOLUME ANALYZER
15 mars 2021 08h30 HE
|
Daxor Corporation
BREAKTHROUGH PATENT-PENDING TRACER DEVELOPED FOR BROAD USE NEW YORK, March 15, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement...
Daxor to Present at the H.C. Wainwright Global Life Sciences Conference
04 mars 2021 08h30 HE
|
Daxor Corporation
NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, announces today that President and CEO Michael Feldschuh will...
DAXOR CORPORATION RECEIVES ISO 13485 QUALITY MANAGEMENT SYSTEM CERTIFICATION FOR THE BLOOD VOLUME ANALYZER (BVA-100®)
19 févr. 2021 08h30 HE
|
Daxor Corporation
Important Milestone for International Distribution NEW YORK, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, announces...
DAXOR CORPORATION AWARDED GRANT FROM THE CENTER FOR ADVANCING POINT OF CARE TECHNOLOGIES (CAPCAT) TO DEVELOP A POINT-OF-CARE BLOOD VOLUME ANALYZER
05 févr. 2021 08h30 HE
|
Daxor Corporation
NEW YORK, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, announces today that it has been awarded a grant from the...
Daxor to Present at the Inaugural H.C. Wainwright BioConnect 2021 Conference
08 janv. 2021 08h30 HE
|
Daxor Corporation
NEW YORK, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology (organized as an investment company with fully-owned...
THIRD HOSPITAL JOINS MULTICENTER COVID-19 BVA-100® BLOOD TEST STUDY
19 nov. 2020 08h30 HE
|
Daxor Corporation
NEW YORK, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume...
OREGON HEALTH & SCIENCE UNIVERSITY JOINS MULTICENTER COVID-19 BVA-100® STUDY
29 oct. 2020 08h30 HE
|
Daxor Corporation
COVID-19 Investigation Continues at OHSU to Study Hospitalized Patients Utilizing Daxor’s Blood Volume Analysis Technology NEW YORK, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT:...
Daxor to Present at the 2020 MicroCap Rodeo Best Ideas Bowl
12 oct. 2020 08h30 HE
|
Daxor Corporation
NEW YORK, NY, Oct. 12, 2020 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume...
New Research Demonstrates Daxor BVA-100® Blood Test Provides “Extremely Cost-Effective” Improvement in Patient Life Span at the Heart Failure Society of America Annual Scientific Meeting 2020
05 oct. 2020 08h30 HE
|
Daxor Corporation
NEW YORK, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume...
New Data Released from the Mayo Clinic Utilizing Daxor’s BVA-100® Test Highlights Value of Daxor’s Diagnostic at the Heart Failure Society of America Virtual Annual Scientific Meeting 2020
02 oct. 2020 08h30 HE
|
Daxor Corporation
NEW YORK, Oct. 02, 2020 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume...